Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Crosses Below 200 Day Moving Average – Time to Sell?

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) shares passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $2.35 and traded as low as $2.31. Oramed Pharmaceuticals shares last traded at $2.33, with a volume of 30,850 shares traded.

Analyst Ratings Changes

Separately, StockNews.com lowered Oramed Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, February 19th.

Oramed Pharmaceuticals Stock Down 2.5 %

The firm has a market capitalization of $92.72 million, a price-to-earnings ratio of 20.91 and a beta of 1.61. The firm’s 50 day moving average is $2.30 and its 200 day moving average is $2.35.

Institutional Investors Weigh In On Oramed Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of ORMP. Boothbay Fund Management LLC increased its stake in Oramed Pharmaceuticals by 2.0% in the 4th quarter. Boothbay Fund Management LLC now owns 845,188 shares of the biotechnology company’s stock worth $2,045,000 after purchasing an additional 16,857 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Oramed Pharmaceuticals by 143.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 118,995 shares of the biotechnology company’s stock worth $288,000 after buying an additional 70,190 shares during the period. BML Capital Management LLC increased its position in shares of Oramed Pharmaceuticals by 20.9% in the fourth quarter. BML Capital Management LLC now owns 2,643,907 shares of the biotechnology company’s stock worth $6,398,000 after acquiring an additional 457,716 shares in the last quarter. World Equity Group Inc. acquired a new stake in shares of Oramed Pharmaceuticals during the fourth quarter valued at approximately $48,000. Finally, Peapod Lane Capital LLC purchased a new stake in shares of Oramed Pharmaceuticals in the 4th quarter valued at approximately $550,000. 12.73% of the stock is owned by institutional investors and hedge funds.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.